Glepaglutide
A long-acting GLP-2 analogue in late-stage development for short bowel syndrome, designed for twice-weekly rather than daily injection.
Design
Glepaglutide carries a C-terminal lysine extension that promotes self-association into a depot at the injection site, releasing peptide slowly and removing the need for daily dosing.
PRIMARY SOURCES
- 01Glepaglutide programme— ClinicalTrials.gov
Educational reference only. Trial figures are protocol-condition means, not individual predictions. Investigational compounds are not approved medicines and have no legitimate consumer supply route.